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1. Introduction  
Autoimmune disease is an aberrant response of the immune system to self. Unlike the 
adaptive immune system, the innate immune system is not selected during development 
and was originally thought to inherently discriminate between host and foreign molecular 
structures (Janeway, 1989). This is true for many innate immune receptor ligands including 
lipopolysaccharide, which is only synthesized by Gram-negative bacteria. However, some 
innate immune receptors detect nucleic acids that are shared between microbes and the host. 
Immune complexes containing nucleic acids are a hallmark of Systemic Lupus 
Erythematosus (SLE), and the nucleic acid sensing Toll-like receptors (TLRs) respond to the 
DNA and RNA within these complexes thereby contributing to disease. Defects in 
regulation of this class of innate immune receptors likely play a key role in precipitation of 
disease. Here we review nucleic acid sensing TLRs in SLE and recent advances in our 
understanding of the regulatory mechanisms governing TLR activity. Since breakdown of 
regulatory mechanisms controlling response of nucleic acid-sensing TLRs likely contributes 
to development of SLE, targeting specific proteins in these regulatory pathways has the 
potential to block nucleic acid-driven autoimmune inflammation. 
2. Nucleic acid sensing toll-like receptors in SLE 
2.1 Toll-like receptors 
Toll-like receptors (TLRs) are a family of innate immune receptors that directly detect 
molecular structures and initiate signaling. Engagement of TLRs initiates innate immune 
responses that promote microbial killing and antigen presentation to educate T cells and B 
cells. At least 10 different TLRs recognize various microbial structures such as lipopeptides 
(TLR1, TLR2, and TLR6), lipopolysaccharide (TLR4), bacterial flagellin (TLR5), double 
stranded RNA (dsRNA, TLR3), single stranded RNA (ssRNA, TLR7, TLR8), and single 
stranded DNA (ssDNA, TLR9) (Takeda, et al. 2003).  
TLRs are type 1 transmembrane receptors with C-termini facing the cytoplasm of the cell 
and ectodomains either at the cell surface or in the lumen of intracellular compartments. The 
cytoplasmic domain has homology with the IL-1 and IL-18 receptors and has been called the 
Toll/IL-1-like receptor domain (TIR). The three-dimensional structures of two TLR 
cytoplasmic TIR domains have been solved and are globular with many surfaces for protein-
protein interactions (Xu, et al. 2000). The TIR domain associates with several adapter 
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proteins that initiate signal transduction. These adapters include myeloid differentiation 
factor 88 (MyD88), and TIR-domain-containing adapter-inducing interferon-β (TRIF, also 
known as MyD88 adapter-like, MAL), which promote production of proinflammatory 
cytokines and type I interferons. The ectodomain is composed of a series of leucine rich 
repeats that form a curved solenoid. Alignment studies predicted a model structure for the 
ectodomains of TLRs (Bell, et al. 2003), which was supported by crystallographic studies 
(Bell, et al. 2005; Choe, et al. 2005). TLRs are expressed on a wide variety of cell types 
including B cells, T cells, dendritic cells, macrophages, and intestinal epithelial cells, 
although different cell types have unique repertoires of TLR expression (Takeda, et al. 2003). 
For example, human plasmacytoid dendritic cells express the nucleic acid-sensing TLRs, 
TLR7 and TLR9. TLR7- and TLR9-dependent responses by both B cells and plasmacytoid 
dendritic cells have been proposed to contribute to SLE (Marshak-Rothstein, 2006).  
2.2 Nucleic acids as TLR ligands 
Multiple nucleic acids, including ssRNA, dsRNA, and DNA, induce inflammatory 
responses. For DNA, the response is dependent on a 5’- cytosine-guanosine-3’ dinucleotide 
(CpG). The central cytosine must be unmethylated, and is active when surrounded by 
specific bases, which together form the CpG motif (Krieg, 2002). These CpG motifs are rare 
in vertebrate DNA due to reduced frequency of the CG dinucleotide (CpG suppression) and 
increased frequency of cytosine methylation (Cardon, et al. 1994; Klinman, et al. 1996; Krieg, 
et al. 1995).  However, CpG motifs are present and functional in bacterial DNA, in plasmid 
DNA produced in bacteria, and in synthetic DNA. Variation of sequence and physical 
structure of synthetic DNAs have resulted in characterization of at least four types of CpG 
oligodeoxynucleotides each with different activity on cells. Three are stimulatory, and one is 
inhibitory (Gursel, et al. 2003; Verthelyi, et al. 2001). Inhibitory DNAs do not require a CpG 
motif and the mechanism of inhibition has not been clearly defined (Gursel, et al. 2003; 
Krieg, et al. 1998; Lenert, et al. 2003). Type A CpG DNAs (also called D) induce robust type I 
interferon production, while type B CpG DNAs (also called K) induce B cell proliferation 
and proinflammatory cytokine production (Verthelyi, et al. 2001). The last class type C CpG 
DNAs have properties of both type A and type B CpG DNAs and thus induces both types of 
cellular responses (Vollmer, et al. 2004).  
Regardless of their class, CpG DNAs require endocytosis and acidification of endosomes for 
activity (Figure 1). Blockade of uptake by immobilization of the CpG DNA on beads inhibits 
the B cell proliferative activity of synthetic CpG DNAs (Manzel & Macfarlane, 1999). 
Inhibition of endosomal acidification blocks CpG DNA-induced cytokine release by 
macrophages (Hacker, et al. 1998). Furthermore, cellular activation by CpG DNA initiates on 
endosomes (Ahmad-Nejad, et al. 2002). Vertebrate DNAs are poorly internalized, which 
contributes to their poor stimulatory activity. However, vertebrate DNA is stimulatory 
when in complex with proteins such as high mobility group box 1 (HMGB1), the 
antimicrobial peptide LL37, or anti-DNA antibodies (Lande, et al. 2007; Leadbetter, et al. 
2002; Tian, et al. 2007). Whether the CpG DNA induces proinflammatory cytokines or type I 
interferon also depends on the endosomal compartment where the DNA is retained (Honda, 
et al. 2005). Honda and colleagues demonstrated that different types of DNA were trafficked 
to and retained within different endosomal compartments. For example, the type I 
interferon inducing CpG DNAs (type A) rapidly co-localized with FITC-dextran, a marker 
for early endosomes, but failed to co-localize with lysosomal markers. In contrast, rapid 
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localization with lysosomal markers correlated with proinflammatory cytokine production 
induced by type B CpG DNAs. In another study the outcome of cellular responses to the 
DNA types could be swapped by changing the physical and chemical properties of the DNA 
(Guiducci, et al. 2006). Multimerization of type B CpG DNAs, so that their physical structure 
resembled type A CpG DNAs, caused them to be retained in early endosomes and induce 
A-type responses. Response of B cells was also dependent on CpG DNA type and delivery 
mechanism (Avalos, et al. 2009). These studies strongly correlated location of DNA detection 
with cellular outcome and suggested that manipulation of localization and receptor 
recognition could change the outcome of cellular response. 
 
DNA Uptake
Host DNA
Degraded:
DNase
Stabilized:
LL37
HMGB1
anti-nuclear antibody
CpG DNA
Endocytosed
endosomal activation of TLR9
 
Fig. 1. DNA uptake into the cell. Host DNA is degraded in the extracellular space by DNase 
and does not normally induce inflammatory responses. However, several host proteins 
including LL37, HMGB1, and anti-nuclear antibodies stabilize host DNA and facilitate 
uptake into the endosomal compartment. Endocytosed host DNA activates TLR9. Unlike 
host DNA, synthetic CpG DNAs, or bacterial DNA, are efficeintly endocytosed and  
activate TLR9.  
At concentrations of CpG DNA used by many investigators, uptake occurs by fluid phase 
endocytosis. Uptake of CpG DNA reached a plateau at 2 hours, was slowed at low 
temperature and was inhibited by known endocytosis inhibitors such as sodium azide and 
cytochalasin B (Yakubov, et al. 1989). Yet, at lower concentrations, uptake was significantly 
more efficient, which indicated that the CpG DNA was internalized by receptor-mediated 
endocytosis. Using radiolabeled cells, multiple groups demonstrated specific DNA binding 
proteins that likely assisted in internalization and trafficking of CpG DNA to the correct 
endosomal compartment where it encountered TLR9 (Beltinger, et al. 1995; Yakubov, et al. 
1989). However, the identity of these receptors remains unknown. During the 
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internalization process, CpG DNA transits though both early and late endosomes, which is 
important because, as mentioned above, CpG DNAs trigger different cellular outcomes 
depending on the compartment where signaling initiates.  
A hallmark of SLE is elevated serum antibodies to nuclear components, which enhance 
response to DNA (Leadbetter, et al. 2002). Immune complexes from SLE patient serum were 
enriched in CG content within the DNA, consistent with increased presence of potential 
stimulatory motifs (Sano & Morimoto, 1982). Complexes with DNA bound to anti-idiotype 
B cell receptors (rheumatoid factor) and to Fc receptors to mediate internalization (Boule, et 
al. 2004; Leadbetter, et al. 2002). By either mechanism the uptake was very efficient and 
delivered the complexes to the endosomal compartment. Synergistic cytokine production 
and autoantibody induction by enhanced uptake of DNA-containing immune complexes 
likely contributes to the induction and propagation of anti-nucleic acid antibody production 
so frequently observed in SLE.  
Internalization of CpG DNA and host DNA is also facilitated by several other host proteins 
including high mobility group protein 1 (HMGB-1), and the antimicrobial peptide LL37. The 
cationic antimicrobial peptide LL37 was highly elevated in the skin of patients with 
psoriases (Lande, et al. 2007). LL37 formed a stable complex with host DNA, and induced a 
TLR9-dependent, DNase-sensitive, type I interferon response from human plasmacytoid 
dendritic cells. The nuclear factor HMGB1 is retained within cells under normal conditions, 
but cell death and inflammation releases HMGB1, which formed a stable complex with host 
DNA. Association of CpG DNA-A with HMGB1 dramatically enhanced production of type I 
interferon (Tian, et al. 2007). In fact, HMGB1 was found in immune complexes with host 
DNA. Altogether, these studies demonstrate that while host DNA alone is not very 
immunostimulatory, association with a variety of different proteins, present in disease 
states, promote endosomal uptake where the DNA can associate with TLRs and induce 
pathologic interferon responses.  
2.3 The role of TLRs in B cells and DC in SLE models 
Mouse models have provided significant experimental evidence for the importance of TLRs 
in SLE. Deficiency in UNC93B1, a chaperone-like protein required for endocytic trafficking 
of nucleic acid-sensing TLRs, results in less severe disease in induced models of SLE in mice 
(Kono, et al. 2009). Furthermore, UNC93B1 protein is upregulated in SLE (Nakano, et al. 
2010), underscoring the importance of TLRs in disease manifestations. The Y-linked 
autoimmune accelerator (Yaa) mutation, which accelerates and enhances spontaneous 
disease on the B6/FcRIIB -/- background, is due to TLR7 gene duplication (Pisitkun, et al. 
2006), and disease in Fas-deficient MRL/lpr mice is dependent on TLR7 expression 
(Christensen, et al. 2006). Together these studies show that nucleic acid-sensing TLRs 
contribute to SLE. 
The role for TLR9 in SLE-like disease in mice is less clear. TLR9 deficient mice have reduced 
anti-DNA antibodies, but enhanced disease (Christensen, et al. 2005). Despite these 
limitations, much is known about the regulation of TLR9, and TLR9 remains a good model 
to study the regulation of nucleic acid-sensing TLRs. A specific role for TLR9 in B cell 
responses to DNA containing immune complexes was supported by studies using a mouse 
expressing a transgenic “rheumatoid factor” receptor. In vitro stimulation with immune 
complexes that included DNA, such as anti-nucleosome complexes, induced proliferation of 
the transgenic B cells, but non-nucleic acid complexes, such as BSA-anti-BSA complexes did 
not. The response was DNase sensitive and dependent on MyD88 and uptake of the 
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immune complexes into the endosomal compartment (Leadbetter, et al. 2002). Therefore, 
while TLR9 may not be a major contributor to disease in patients, defects in TLR9 regulation 
may have very specific functional consequences and a better understanding of the 
regulatory mechanisms may provide necessary information to therapeutically target TLR9 
and other nucleic acid-sensing TLRs.  
Patients with SLE have high levels of type I interferons in the blood and their peripheral 
blood mononuclear cells have a characteristic upregulation of interferon regulated genes 
(Bennett, et al. 2003). Plasmacytoid dendritic cells circulating in the blood are a major source 
of type I interferons and were originally called natural interferon producing cells (NIPCs). 
In humans, this subset of dendritic cells expresses predominantly TLR7 and TLR9 
(Hornung, et al. 2002; Krug, et al. 2004). Production of type I interferons by plasmacytoid 
dendritic cells can be induced by immune complexes produced in abundance in patients 
with SLE (Ronnblom & Alm, 2001). Dendritic cells have Fc receptors on their cell surface 
that capture and internalize immune complexes, which induces interferon in a CpG motif- 
and TLR9-dependent manner (Boule, et al. 2004; Yasuda, et al. 2009). High circulating type I 
interferon correlates with immune pathology and disease severity in SLE. Therefore, TLR9 
contributes to interferon production, and interferon can in turn augment TLR9-dependent 
responses.  
2.4 Nucleic acid-sensing TLRs detection of self-ligands 
When the stimulatory activity of CpG DNA was first described, it was thought to represent 
microbial DNA and that self-DNA was non-stimulatory. This was due to the requirement 
for the central CG dinucleotide, unmethylation of the C, and for selectivity for surrounding 
bases. These arguments held for many years, but it was known, even then, that the 
mammalian genome had the potential to induce TLR9-mediated responses (Ishii, et al. 2001; 
Yasuda, et al. 2005). Many studies, including the ones reviewed below, have been focussed 
on understanding what regulates TLR9 mediated responses and why self-DNA is not 
normally detected. However, recent studies suggest that TLR9 signaling is important for 
normal responses like wound repair. 
Cells go to great lengths to assure DNA is not released into the extracellular milieu when 
they die by condensing and digesting their DNA during apoptosis. However, necrosis 
and neutrophil extracellular trap (NET) formation intentionally releases DNA that can 
induce inflammatory responses (Garcia-Romo, et al. 2011; Lande, et al. 2011; Villanueva, 
et al. 2011). Interestingly, SLE neutrophils were primed by high type I interferon levels in 
vivo, and in response to immune complexes, the neutrophils from SLE patients generated 
NETs that had a high content of DNA, LL37 and HMGB1. These proteins protected the 
DNA from degradation and facilitated internalization, and thereby increased the 
inflammatory potential of the host DNA. Therefore, since it is purposefully released 
under certain conditions, there must be other regulatory mechanisms to avoid response to 
host DNA. DNase is present in serum and in the extracellular environment and degrades 
potentially stimulatory host DNA. DNase deficient mice were born healthy but develop 
lupus like disease around six months of age (Napirei, et al. 2000). Heterozygous mice had 
increased serum concentrations of anti-nuclear antibodies, and more glomerulonephritis. 
However, in homozygous DNase deficient mice these SLE parameters were even higher. 
Mutations in DNase have been identified in SLE patients (Yasutomo, et al. 2001), and 
together these studies suggest that DNase is an important mechanism to prevent response 
to host DNA.  
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Interestingly, recent studies have shown that detection of self-DNA may be a normal 
biological process, and is, in fact, critical for wound healing (Gregorio, et al. 2010; Sato, et 
al. 2010). In the absence of TLR9, full thickness biopsy wound healing was delayed, and 
application of CpG DNA enhanced healing in a TLR9 dependent manner (Sato, et al. 
2010). These data suggest that TLR9 plays an important role in wound healing. In a 
different model, tape stripping-induced epidermal injury induced plasmacytoid dendritic 
cell and neutrophil infiltration (Guiducci, et al. 2010). This response was accompanied by 
production of type I interferon, and was dependent on the signaling adapter molecule 
MyD88. Treatment of wild-type mice with a TLR7-TLR9 inhibitor inhibited the response, 
implicating these TLRs in the process. In lupus-prone mice, the same tape-stripping 
procedure led to chronic wounds with a type I interferon signature that resembled SLE 
skin lesions. Therefore, detection of DNA and RNA by TLR9 and TLR7 is important for 
normal wound healing. Dysregulation of this pathway in SLE likely contributes to 
autoimmune inflammation, especially in the skin, and is a potential target for therapeutic 
intervention.  
3. Regulation of TLR9  
3.1 Compartmentalization of TLR9 
Infectious agents replicate in various locations outside and inside cells. Bacteria and 
viruses are internalized into endosomes, and some can escape into the cytoplasm. 
Therefore, positioning of TLRs is important for detecting components of microbes in the 
varied locations where they can reside. Some TLRs, such as TLR2, TLR4, and TLR5, are 
expressed at the cell surface to detect ligands expressed on the surface of bacteria 
(lipopolysaccharide, TLR4; lipopeptides, TLR2; and flagellin, TLR5). However, nucleic 
acids, such as DNA and RNA, are encapsulated within bacteria and viruses, and are only 
released upon internalization into endosomes. To accommodate this, nucleic acid sensing 
TLRs are localized intracellularly. For example, TLR9 is primarily found in the 
endoplasmic reticulum (ER) of resting cells (Latz, et al. 2004; Leifer, et al. 2004) where it 
colocalizes with ER, and not endosomal, markers. Since detection of DNA occurs in 
endosomes, these data suggest that that there is an induced trafficking event that leads to 
TLR9 entry into this compartment (Leifer, et al. 2004). The unique compartmentalization 
of nucleic acid-sensing TLRs has been proposed as a major regulatory mechanism to 
prevent response to host DNA (Barton, et al. 2006). Fusion of the ectodomain of TLR9 
with the transmembrane domain and cytoplasmic tail of TLR4 created a protein that 
localized to the cell surface. This change in localization endowed the TLR9 ectodomain 
with the ability to respond to host DNA (Barton, et al. 2006). These data support a model 
where TLR9 is specifically trafficked intracellularly to avoid access to the extracellular 
milieu, thereby preventing recognition of host DNA.   
3.2 Trafficking of TLR9 through the Golgi to localize in the endolysosomes 
While TLR9 predominantly resides in the ER it must traffic to the endosomal compartment 
where it encounters endocytosed CpG DNA (Latz, et al. 2004; Leifer, et al. 2004) (Figure 2). 
Normally, transmembrane or secreted proteins synthesized in the ER traffic through the 
Golgi to access the cell surface or intracellular endosomes. However, TLR9 was sensitive to 
endoglycosidase H (endo H) treatment, which indicated that TLR9 had not reached the 
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Golgi (Latz, et al. 2004). In 2009 Chockalingam et al., showed that Brefeldin A inhibited 
TLR9 response to CpG DNA (Chockalingam, et al. 2009). Since Brefeldin A is a small 
molecule that inhibits transport of proteins from ER to Golgi, TLR9 signaling appeared to be 
dependent on Golgi trafficking.  
When proteins traffic through the Golgi, the high mannose glycans are processed to 
hybrid forms that are still cleaved by Endo H; therefore, highly specific lectins were used 
to determine whether TLR9 had glycan modifications indicative of Golgi transit 
(Chockalingam, et al. 2009). Lectins are plant proteins that selectively recognize 
carbohydrate structures. For example, Datura stramonium (DS) lectin specifically 
recognizes “Galβ1→4GlcNac” structures present only on proteins that have been 
processed by Golgi resident enzymes. DS lectin bound to TLR9, which confirmed that 
TLR9 trafficked through the Golgi during synthesis (Chockalingam, et al. 2009). TLR9 
immunoprecipitated from the lysosomal compartment of HEK293 cells also bound DS 
lectin, and co-immunoprecipitated with the signaling adapter MyD88 (Chockalingam, et 
al. 2009). These data indicated that lysosomal TLR9 had transited through the Golgi and 
contributed to signaling.  
 
Golgi
ER
endosome
gp96
CNPY3(PRAT4A)
AP3
UNC93B1
sorting vesicle
proteolytic processing
 gp96
tyrosine motif
 
Fig. 2. Regulation of TLR9 trafficking. After synthesis in the ER TLR9 associates with gp96. 
TLR9 traffics out of the ER to the Golgi in a manner dependent on gp96, PRAT4A, and 
UNC93B1. TLR9 traffics from the Golgi to a sorting vesicle in an AP3 dependent manner 
where it is then sorted to the endosomal compartment via a cytoplasmic tyrosine motif. In 
the endosomal compartment TLR9 is proteolytically processed either active or negative 
regulatory forms that modulate TLR9 signaling. Lack of gp96 prevents TLR9 proteolytic 
processing. 
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3.3 Proteins that regulate intracellular localization and trafficking 
Several proteins are critical for TLR9 trafficking both out of the ER and to the endosomal 
compartment (Figure 2): UNC93B1, adapter protein 3 (AP3), a protein associated with TLR4 
(PRAT4A), Slc15a4, and glycoprotein 96 (gp96, also known as glucose regulated protein 94 
(gp94). Recessive N-ethyl-N-nitrosourea-induced mutagenesis revealed a mouse line that 
lacked response to TLR3, TLR7, and TLR9 ligands. These mice had a single point mutation 
(H412R) in UNC93B1 (Tabeta, et al. 2006). In dendritic cells from these mice, TLR7 and TLR9 
did not localize to the endosomal compartment (Kim, et al. 2008). Interestingly, UNC93B1 
seems to play opposing roles in regulation of TLR7 and TLR9 (Fukui, et al. 2009). 
Reconstitution of UNC93B1 deficient cells with UNC93B1 containing a single point mutation 
(D34A) resulted in hyperresponsivenss to TLR7, yet hyporesponsiveness to TLR9, ligands. 
Therefore, the role of UNC93B1 in regulation of nucleic acid sensing TLRs is clearly 
important and interfering with UNC93B1 function has different effects on signaling by 
different TLRs. 
Two ER luminal proteins, gp96 and PRAT4A, are essential for TLR9 exit from the ER. 
PRAT4A, also known as CNPY3, bound to TLR9, which depended on methionine 145 of 
PRAT4A (Kiyokawa, et al. 2008). In the absence of PRAT4A, TLR9 did not access 
endosomes, and PRAT4A deficient cells lacked response through all TLRs, except TLR3 
(Takahashi, et al. 2007). The heat shock protein gp96 also bound to TLR9 and was required 
for B cell and macrophage response to CpG DNA (Randow & Seed, 2001; Yang, et al. 2007). 
A pre-B cell line with a frame-shift mutation in gp96 was 10,000 times less sensitive to LPS 
then the non-mutant line, which was due to a lack of TLR4 on the cell surface (Randow & 
Seed, 2001). This study suggested that gp96 regulated trafficking of TLRs. Further studies 
using a mouse with macrophage specific knockout of gp96 showed that gp96 is essential for 
TLR9 trafficking and signaling, and was in fact a chaperone for all TLRs except TLR3 (Liu, et 
al. 2010; Yang, et al. 2007). In 2011 Liu et al., demonstrated that gp96 and PRAT4A directly 
interacted to form a multimeric complex with TLR9 (Liu, et al. 2010). Very recent studies 
using gp96 specific inhibitors have examined the role of gp96 after TLR9 synthesis and 
trafficking is complete. These studies show that gp96 remains associated with TLR9 in the 
endosomal compartment and that specific inhibitors block CpG DNA signaling and cause a 
loss of TLR9 protein (JC Brooks and CA Leifer unpublished observations). This suggests that 
gp96 has an additional function in regulating the conformational stability of TLR9 in the 
endosomal compartment.   
Cytoplasmic proteins are also important for TLR9 trafficking. Plasmacytoid DCs from 
adapter protein 3 (AP3) deficient mice failed to induce a type I interferon response after 
CpG DNA stimulation despite normal IL-12 production (Sasai, et al. 2010). AP3 is a 
cytosolic protein that associates with endosomes and sorts transmembrane proteins from 
the endosomal compartment to lysosome-related organelles (Bonifacino & Traub, 2003).  
In the absence of AP3, TLR9 did not colocalize with markers for lysosome-related 
organelles (Sasai, et al. 2010). This group suggested that it was these lysosome-related 
organelles that were critical for induction of type I interferons (Sasai, et al. 2010). 
However, this conclusion contradicts previously published studies showing that initiation 
of signaling that results in type I interferon production occurs on early endosomes 
(Guiducci, et al. 2006; Honda, et al. 2005). In a separate study using the same AP3 
deficient mice, both proinflammatory and type I interferon production were lost. 
Therefore, AP3 is important for TLR9-induced cytokine production, but its exact role in 
TLR9 biology remains unclear. 
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Recent data have shown that TLR9 signaling also depends on Slc15a4, a twelve-spanning 
transmembrane oligopeptide transporter that localizes to the endolysosomal compartment 
(Blasius, et al. 2010; Yamashita, et al. 1997). Cells from Slc15a4 deficient mice lack response 
to nucleic acid sensing TLRs (Blasius, et al. 2010). Again, the specific role of Slc15a4 remains 
unknown, but may involve endolysosomal transport of TLR9 or a TLR9-associated protein 
required for TLR9 function.  
3.4 Specific motifs in TLR9 that regulate localization and trafficking 
Localization of TLRs is regulated by sequences in their transmembrane domains and 
cytoplasmic tails. Fusion of TLR4 to the transmembrane and cytoplasmic tail of various 
TLRs resulted in distinct localizations of the chimeric proteins (Nishiya & DeFranco, 2004). 
For example, TLR4 by itself localized to the cell surface, and fusion of TLR4’s ectodomain 
with the transmembrane and cytoplasmic tail of TLR1, TLR2, TLR5, or TLR6 resulted in 
similar localization. In contrast, when TLR4 was fused to the transmembrane and 
cytoplasmic tail of any of the nucleic acid-sensing TLRs, the resulting chimeric receptor was 
not detected at the cell surface. Further studies using different approaches identified 
different motifs in TLR9 responsible for this localization (Barton, et al. 2006; Leifer, et al. 
2006). TLR9’s ectodomain fused to TLR4’s transmembrane and cytoplasmic domains 
localized to the cell surface (Barton, et al. 2006). The chimera retained the ability to respond 
to CpG DNA, yet was resistant to endosomal acidification inhibitors. Interestingly, TLR9 
associates with UNC93B1 via the transmembrane domain and this may explain, in part, the 
requirement for this association in TLR9 signaling.  
The cytoplasmic tail of TLR9 also contains a specific localization motif (Leifer, et al. 2006). In 
this study, the ectodomain of the IL-2 receptor alpha chain, which normally localized to cell 
surface, was fused to the transmembrane and cytoplasmic tail of different TLRs (Leifer, et al. 
2006). A fusion with the TLR4 transmembrane and cytoplasmic tail localized to the cell 
surface; however, a fusion with the same regions of TLR9 was not. Truncation analysis 
revealed that deletion of all but four amino acids of the cytoplasmic tail generated a protein 
that was robustly expressed at the cell surface, ruling out a contribution of the 
transmembrane domain to intracellular localization. It is unclear why these two studies 
showed opposite requirements for TLR9 transmembrane domain. Regardless, additional 
truncations and mapping identified a 14 amino acid motif that was important for TLR9 
intracellular localization. Follow-up studies showed that mutation of a critical tyrosine (888) 
within this motif abolished proinflammatory cytokine production. Interestingly, this mutant 
maintained normal interferon responses suggesting that this motif was required for 
trafficking TLR9 to the compartment selectively required for induction of proinflammatory 
cytokines (A Chockalingam and CA Leifer unpublished observations). It remains to be 
determined if this motif is necessary for association with AP3 or other regulatory proteins. 
3.5 Proteolytic regulation of TLR9 
In addition to trafficking to specific endocytic compartments, several recent studies have 
demonstrated that TLR9 is proteolytically processed in endosomes and that this processing 
regulates TLR9 function (Chockalingam, et al. 2011; Ewald, et al. 2011; Ewald, et al. 2008; 
Park, et al. 2008; Sepulveda, et al. 2009). The ectodomain of TLR9 contains 25 leucine rich 
repeats. The first 14 and the second 15 leucine-rich repeats are interrupted by a region 
predicted to have very little secondary structure, often referred to as the hinge (Bell, et al. 
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2003). The first described proteolytic event was mapped to this hinge region through a mass 
spectrometric approach (Park, et al. 2008). The form of TLR9 generated encompasses one-
half of the ectodomain and all of the transmembrane and cytoplasmic tail (Figure 3). This 
proteolytic event is inhibited by endosomal acidification inhibitors and by broad-spectrum 
cathepsin inhibitors (Ewald, et al. 2008; Park, et al. 2008). Additional studies with specific 
cathepsin inhibitors, and in cathepsin deficient mice, did not reveal a unique cathepsin 
responsible for the cleavage. An independent study, showed an additional proteolytic event 
(Sepulveda, et al. 2009). While this study did not reveal the precise location of the 
proteolysis, a specific enzyme, asaparagine endopeptidase was shown to be important. A 
more recent study suggested that stepwise processing of TLR9 is required to attain fully 
functional proteolytically processed TLR9 (Ewald, et al. 2011). Interestingly, knockdown of 
either PRAT4A (CNPY3) or gp96 by shRNA targeting resulted in a loss of proteolytic 
processing of TLR9, and suggested that these chaperones were required for TLR9 to access 
endosomes (Liu, et al. 2010).  
 
 
Fig. 3. Proteolytic processing of TLR9. The ectomain of TLR9 is proteolytically processed 
into two forms. The first form is active and consists of one half of the ectodomain of TLR9 
and the transmembrane and cytoplasmic tail (amino acids 471-1032) The second form is a 
negative regulator of TLR9 signaling and consists of almost the entire ectodomain with no 
transmembrane or cytoplasmic tail. This form, called soluble TLR9, is released into 
endosomes, but is not secreted. By binding to internalized DNA, and to full-length TLR9, 
this form blocks signaling. The relative ratio of these two fragments likely determines the 
cellular response upon exposure to DNA.  
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TLR9 is also proteolytically processed at a completely different position to generate a 
negative regulator of TLR9 signaling (Chockalingam, et al. 2011). This proteolytic event 
resulted in generation of an intact ectodomain separated from the transmembrane domain 
and cytoplasmic tail (Figure 2). This soluble form of TLR9 bound to CpG DNA, associated 
with full length TLR9, and dominant negatively inhibited responses by the full-length 
receptor (Chockalingam, et al. 2011). In contrast to the other proteolytic cleavage events, 
generation of soluble TLR9 occurred in cells expressing endogenous TLR9 (Chockalingam, 
et al. 2011). Soluble TLR9 is likely important in regulating TLR9 responses since intestinal 
epithelial cells poorly responded to CpG DNA, and abundantly generated soluble TLR9 
(Chockalingam, et al. 2011). Therefore, correlative studies on TLR9 in different 
pathological conditions must account for the complexity of TLR9 post-translational 
modification.  
4. Conclusion  
In this review we have highlighted recent studies describing regulatory mechanisms 
governing nucleic acid-sensing TLRs. While TLRs are critical for host defence against 
infection, some TLRs recognize ligands shared between infectious agents and the host 
(Marshak-Rothstein & Rifkin, 2007). Despite complex regulatory mechanisms, these TLRs do 
contribute to autoimmune disease (Marshak-Rothstein, 2006). Recent studies have revealed 
multiple post-translational mechanisms that regulate this family of TLRs, and if 
dysregulated could also contribute to the development of autoimmune disease. By 
exploiting mechanisms that control nucleic acid sensing TLRs we will relieve TLR-mediate 
autoimmune inflammation.  
Host DNA and RNA are not typically inflammatory since there are several regulatory 
mechanisms to prevent availability of host DNA. These include preventing its release 
(apoptosis), and degrading it once it is released (DNase). Association with various host 
proteins such as HMGB1, LL37, and autoantibodies stabilize host DNA and enhance its 
uptake where it gains access to intracellular nucleic acid sensing TLRs (Lande, et al. 2007; 
Leadbetter, et al. 2002; Tian, et al. 2007). When this occurs, especially by anti-nuclear 
antibodies, host DNA and RNA enhance type I interferon production from dendritic cells 
and promote proliferation and antibody production from B cells. Defects in expression of 
the nucleic acid stabilizing proteins changes susceptibility to autoimmunity in mouse 
models. Development of drugs that block stabilization of DNA by these host proteins, and 
thereby block proinflammatory or interferon responses, will reduce autoinflammation and 
offer new ways to treat SLE.  
The nucleic acid-sensing TLRs are also carefully regulated to avoid response to host DNA. 
To avoid detection of host DNAs and RNAs, nucleic acid-sensing TLRs are excluded from 
the cell surface (Latz, et al. 2004; Leifer, et al. 2004). Several proteins including UNC93B1, 
and gp96 regulate nucleic acid-sensing TLR access to endosomes (Kim, et al. 2008; Yang, et 
al. 2007). Specific parts of TLR9 have been found to be important for this regulation and may 
interact with some of the localization regulators (Barton, et al. 2006; Leifer, et al. 2006). 
Development of drugs that affect the activity of these proteins would change the 
intracellular distribution of TLRs, thereby affecting the ability of these receptors to detect 
and respond to nucleic acids. 
Once nucleic acid-sensing TLRs do reach endosomes, they are proteolytically processed 
(Chockalingam, et al. 2011; Ewald, et al. 2008; Park, et al. 2008), which modifies their 
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function. Cleavage at two different locations within the ectodomain leads to either activation 
(Ewald, et al. 2008; Park, et al. 2008), or inhibition (Chockalingam, et al. 2011), of TLR9 
activity. Specific identification of the enzymes responsible for these proteolytic events will 
provide new targets for drug development to interfere with TLR signaling and response to 
host DNA.   
When host DNA, or RNA, does activate a TLR, it induces robust inflammation and 
production of pathologic levels of cytokines such as type I interferon. While several 
contributing factors to the development of SLE have been found, new data on post-
translational regulation of nucleic acid-sensing TLRs show that we still have much to learn. 
Dysregulation in any of these regulatory proteins will change the intracellular localization of 
TLR9 and could potentially lead to aberrant response to host nucleic acids. Identifying these 
regulatory pathways is the first step to understanding how defects in these pathways lead to 
disease. Specifically targeting these regulatory proteins within these pathways will reduce, 
or restore, function as necessary to return the regulatory networks to the non-disease state. 
Therefore, future studies should be focused on improving our understanding of the basic 
regulatory networks for nucleic acid-sensing TLRs so that we may determine which are 
defective in SLE. Our hope is that these studies will lead to novel drug development, and 
improve our repertoire of options to treat autoimmune disease.   
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